Format

Send to

Choose Destination
J Hypertens. 2012 Mar;30(3):617-23. doi: 10.1097/HJH.0b013e32834f0b9f.

Health insurance coverage is the single most prominent socioeconomic factor associated with cardiovascular drug delivery in the French population.

Author information

1
Institut National de la Santé et de la Recherche Médicale, Unité 872, Centre de Recherche des Cordeliers, Paris, France.

Abstract

OBJECTIVE:

Although the French population benefits from universal health coverage, prescribed drugs are in most cases only partially reimbursed by the national insurance plan (65% of the cost), raising the possibility of reduced drug access for patients with low socioeconomic status.

METHODS:

To explore this question, the delivery of cardiovascular drugs in relation to socioeconomic position was analysed in a cross-sectional survey of a nationally representative sample of patients with cardiovascular condition (n = 4646).

RESULTS:

Among eight socioeconomic indicators and after adjustment for healthcare needs, only health coverage is independently associated with cardiovascular drug delivery, which is reduced by half [odds ratio (95% confidence interval): 0.54 (0.39-0.74), P = 0.0001] in patients partially covered by universal health insurance compared with those fully covered by supplemental insurance. This reduced delivery in patients with partial health coverage seems to apply to all cardiovascular drug classes as it is observed for both antihypertensive and hypolipemic drugs when these classes are tested separately. Although physician access is also reduced in patients with partial health coverage [0.54 (0.40-0.75), P = 0.0002], this does not explain the decreased delivery of cardiovascular drugs that is still observed [0.59 (0.43-0.82), P = 0.001] after further adjustment for the number of physician visits during the survey.

CONCLUSION:

These results suggest that health insurance coverage has a prominent role among socioeconomic factors in determining the delivery of prescribed medications as essential as cardiovascular drugs in the French population. They emphasize that full health coverage should remain a priority for public health policies in this country.

PMID:
22227816
DOI:
10.1097/HJH.0b013e32834f0b9f
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center